Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
PSMA-PET imaging is a powerful tool for prostate cancer drug development, enabling precise tumor localization, assessment of PSMA expression, and the ability to monitor therapeutic efficacy.
With the approvals of several PSMA-targeted tracers and therapeutic agents, the industry is undergoing a renaissance. As the leading provider in PSMA-PET imaging solutions with the largest global footprint in the industry – we are your trusted scientific partner, capable of scaling seamlessly from preclinical studies to early and late-phase registrational trials.
PSMA-PET clinical trials supported
PSMA-PET scans analyzed
Preclinical studies supported
Our imaging core lab team delivers streamlined solutions for PSMA-PET clinical trials, enabling sponsors to execute complex studies efficiently while generating high-quality data for regulatory submissions and therapeutic decision-making.
We help drug developers deliver trials on time, on budget, and with the imaging insights needed to move therapies forward.
Our preclinical imaging solutions set the stage for successful clinical translation. By integrating radiochemistry, biodistribution studies, and tumor-targeting imaging, we enable drug developers to optimize their PSMA-targeted agents with confidence.
With expertise across isotopes such as 177Lu, 68Ga, 225Ac, and 18F, our team delivers actionable preclinical insights that accelerate discovery pipelines.
As the only imaging solutions provider to date to support an FDA submission of quantitative PET data using AI, we bring unmatched expertise to your imaging strategy. Perceptive combines advanced imaging platforms with proprietary AI-driven tools to maximize the value of imaging data. Our analytics support whole-body quantification, lesion co-localization, and detailed response assessments for both preclinical and clinical trials.
Our updated, Automated PSMA Segmentation Tool (available April 2025) offers increased automation and flexibility / sensitivity for faster processing times. The enhanced features of Version 2 include:
Perceptive’s AI team is continuing to develop cutting edge solutions to advance imaging and image analysis across the clinical space.
Perceptive provides comprehensive dosimetry services for the development of radiopharmaceuticals, including PSMA-targeted agents. We support both normal organ and tumor dosimetry through well-established workflows that ensure precision and reliability in whole body, organ and tumor radiation dose assessments. Our in-house team and external collaborators include imaging scientists, PSMA-dual certified radiologists, as well as nuclear medicine physicians, who bring specialized knowledge to every project.
Additionally, we are able to ship imaging phantoms to trial sites, enabling standardized imaging calibration and accurate dose calculations, while our robust phantom analysis further enhances the quality of results.
Perceptive offers expertise and a dedicated customer-centric team with years of experience in radiopharmacy networks, shipping and handling, transportation logistics and more with regulatory, quality and project manager backgrounds.
Service offerings include but are not limited to:
With unmatched expertise in PSMA-PET imaging, radioligand therapy, and theranostics, Perceptive empowers drug developers with better prostate cancer biomarkers. From preclinical discovery to late-phase clinical trials, we provide the tools, expertise, and insights to deliver success.
Contact us to learn how our comprehensive imaging solutions can transform your research.
